• AI and Biotechnology: Navigating Opportunities and Risks in the Bioeconomy

    Bio-IT World | Last month’s Bioprocessing Venture, Innovation, and Partnering Conference brought together thought leaders from across the bioeconomy to discuss the rapidly evolving landscape of artificial intelligence (AI) in biotechnology.

    Sep 11, 2024

  • Researchers Add ‘New Piece to the Puzzle’ That is Celiac Disease

    Bio-IT World | Celiac disease is a surprisingly common but substantially underdiagnosed autoimmune disorder estimated to affect 1 in 100 people globally. Left untreated, it can have “serious clinical consequences” for patients, including malnutrition, bone weakening, and potentially even a higher risk of certain cancers.

    Sep 10, 2024

  • Biotech’s Secret to Surviving Economic Challenges? It’s All in the Data & AI

    Bio-IT World | Data has always been crucial in the life sciences industry, but in today's fiercely competitive landscape, its significance has skyrocketed. Amidst dwindling funding and mounting market pressures, biopharmaceutical companies need to better harness the power of information to design and accelerate clinical trials and timelines.

    Sep 6, 2024

  • Amgen’s AI Futures: Digital Twins, Unstructured Data, Human Review

    Bio-IT World | Jerry Murry, senior vice president, process and development, at Amgen, gave the plenary presentation at CHI’s Bioprocessing Summit last month. With an eighteen-year tenure at Amgen—and experience at Merck and Pfizer before that—Murry has seen nearly two decades of advances in the world of bioprocessing and manufacturing.

    Sep 3, 2024

  • NIH Launches Native Collective Research Effort Focused on Overdose

    Bio-IT World | In August, the National Institutes of Health (NIH) has launched the Native Collective Research Effort to Enhance Wellness (N CREW) Program, an effort support Native American communities to lead public health research to address overdose, substance use, and pain, including related factors such as mental health and wellness. The planned program funding totals approximately $268 million over seven years.

    Sep 3, 2024

  • Follow the Money: AI-Powered Cell Therapies, Cancer Risk Assessment, More

    Bio-IT World | Outpace Bio will advance multiple programmed T cell product candidates to early clinical proof-of-concept for the treatment of solid tumors; Foresight Diagnostics plans to accelerate the clinical development and commercialization of their cancer recurrence testing platform, PhasED-Seq; PreciseDx plan to expand commercialization efforts for PreciseBreast risk assessment, an AI-Powered test used to assess early-stage invasive breast cancer risk; and more.

    Aug 29, 2024

  • Dovetail Genomics, Goenomics GmbH Partnership, Danaher Acquires Genedata, Andelyn Biosciences License Agreement With Broad Institute, More

    Bio-IT World |Dovetail Genomics has formed a partnership with Goenomics GmbH to deliver an enhanced genome assembly service with the fastest turnaround time and most complete annotation available in the industry; Genedata has been acquired by Danaher; Andelyn Biosciences has entered into a License Agreement with the Broad Institute of MIT and Harvard to expand its AAV Curator Platform offering to include MyoAAV plasmids; and more.

    Aug 28, 2024

  • Panel Explores the Rapidly Evolving Field of Genetic Medicines

    Bio-IT World | In a panel discussion at last week’s Bioprocessing Summit, four leaders in genetic medicine shared insights into the rapidly evolving world of gene editing and its potential to revolutionize the treatment of complex diseases. In a panel discussion at last week’s Bioprocessing Summit, four leaders in genetic medicine shared insights into the rapidly evolving world of gene editing and its potential to revolutionize the treatment of complex diseases.

    Aug 27, 2024

  • The Art of Building Techbio Teams

    Bio-IT World | The biotech industry is experiencing a significant shift as technology and biology converge. This intersection, often called Techbio, is opening up new possibilities for addressing health and environmental challenges.

    Aug 23, 2024

  • First Clinical Trial of ‘Paradoxical Intervention’ for Cancer to Begin Soon

    Bio-IT World | Cancer cells are “not like superheroes that have no vulnerabilities." Most current therapies try to block the signaling to prevent cancer’s uncontrolled division, but inevitably tumor cells resist the blockage and become far less responsive to subsequent therapy.

    Aug 21, 2024

  • Mice Cleared of Senescent Cells Shown to Die Healthier—Not Just Live Longer

    Bio-IT World | By treating a particular brand of senescent cells, it is now possible to live healthier for longer—at least in mice. If the findings can be translated to humans, that could mean an extra decade of healthiness. Plenty of medicines are already available to help people live longer, but not necessarily with vitality.

    Aug 20, 2024

  • Standardized R&D Data Exchange is Here. Let’s Embrace It.

    Bio-IT World | Life sciences companies have spent much time and treasure working to streamline and improve product development. The drivers have been many, but two have stood out. The first is a desire to improve efficiency and optimize cost, because it’s good for business and the pocketbooks of patients we ultimately serve. The second is to boost material traceability, because product quality depends on it—and regulators demand it.

    Aug 16, 2024

  • A Skeptic Converts: Tom Plasterer’s move from Big Pharma to AI Startup

    Bio-IT World | For more than a dozen years, Tom Plasterer has held roles at AstraZeneca both in research IT and in more science-facing positions including translational medicine. Along the way, he was beating the drum for FAIR data—data that are Findable, Accessible, Interoperable and Reusable— and knowledge graphs, playing an active role in both the FAIR community and the Pistoia Alliance.

    Aug 14, 2024

  • Safe and Intriguing ‘Nature’s Drugs’ Taking on Complex Diseases

    Bio-IT World | The cost of bringing a drug to market has, by some estimates, ballooned to $3 billion and the central problem could be the “misapplication of technology.” Since completion of the Human Genome Project, the focus had shifted heavily toward orphan drugs with a single genetic target, suitable only to highly targeted genetic technology platforms.

    Aug 13, 2024

  • Recursion, Exscientia Merge AI Drug Discovery Companies

    Bio-IT World | Recursion and Exscientia have entered into a definitive agreement to combine Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities.

    Aug 8, 2024

  • Singapore Launches Long-Read Population Sequencing Program with PacBio, Oxford Nanopore

    Bio-IT World | Singapore’s National Precision Medicine (NPM) program has launched a long-read sequencing project to gain deeper insights into Asian genetic diversity. The program, Precision Health Research, Singapore (PRECISE) has appointed both Oxford Nanopore Technologies (ONT) and PacBio (PacBio) to deliver sequencing.

    Aug 8, 2024

  • Howard Jacob on How AbbVie’s ARCH is Unlocking Major Opportunities

    Bio-IT World | At last year’s Bio-IT World Conference & Expo, AbbVie won an Innovative Practices Award for their AbbVie R&D Convergence Hub (ARCH). Their data platform is designed to provide access to knowledge in a faster and more automated way, as well as an easier way to extract insights and connect disparate datasets. Today, three years after the launch of ARCH, AbbVie has made great strides in data convergence with the platform.

    Aug 7, 2024

  • GE HealthCare, AWS Collaborate on Gen AI Models

    Bio-IT World | GE HealthCare and Amazon Web Services have announced a strategic collaboration to develop purpose-built foundation models and generative artificial intelligence (AI) applications designed to help clinicians improve medical diagnostics and patient care.

    Aug 6, 2024

  • BioTeam Acquired by British n2 Group

    Bio-IT World | BioTeam announced its acquisition today by British firm n2 Group. BioTeam will be a US-based, independent business within n2 Group. Financial details have not been disclosed.

    Aug 2, 2024

  • Youth Diabetes Researchers Invited to Dip Into POND, Make a Hypothesis

    Bio-IT World | Soaring rates of youth prediabetes and diabetes over the past few decades have prompted a multidisciplinary team of experts from the Icahn School of Medicine at Mount Sinai (ISMMS) to create a dataset unifying potentially important clues about how to personalize interventions and devise better prevention strategies.

    Aug 1, 2024